Nasopharyngeal carcinoma (NPC) is the most prevalent head and neck malignancy in Indonesia (Adham et aI., 2012). A report based on a five-year analysis indicated that patients usually arrive at the hospital to examine their condition at a late stage of NPC due to the unspecific symptoms in the early stage (Fachiroh et aI., 2004). The treatment of NPC is stage dependent and early detection is imperative in order to achieving higher treatment success (Fachiroh et aI., 2006). Knowing the markers that can be used to detect NPC at an early stage is essential at this time. NPC corresponds to the highest tumor burden that is associated with the Epstein-Barr virus (EBV) infection (Hutajulu et aI., 2014). EBV -based serologies using IgA-based ELISA and IgG immunoblotting as well as EBV DNA viral quantification, which allowed for the development of improved NPC diagnostic tools (Fachiroh et aI., 2006). IgG and IgA antibody responses to EBV antigens in NPC patients are each triggered by different antigen-epitope recognition events and are not clonally related and the immunodominant epitopes (peptides) are best for use in diagnostic testing of Nasopharyngeal Carcinoma. These new EBV related diagnostic tools have excellent diagnostic capabilities in screening NPC patients from the population